Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide in Treating Patients With Leptomeningeal Metastases From a Solid Tumor or Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* Documented leptomeningeal metastases~* Carcinomatous meningitis that is previously untreated or failed prior therapy OR~* Lymphomatous meningitis~* Systemic disease that is responding or stable on current therapy not eligible if discontinuing therapy would be deleterious~* Age 18 and over~* Karnofsky Performance Status 60-100%~* Life expectancy of at least 6 weeks~* Absolute neutrophil count greater than 1,500/μL~* Platelet count greater than 100,000/μL~* Creatinine no greater than 2.0 mg/dL~* No congestive heart failure~* No unstable angina~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No contraindication to diagnostic sampling of CSF via lumbar puncture or reservoir~* No medical conditions that would interfere with absorption of oral medication (e.g., malabsorption, obstruction, or frequent vomiting)~* No uncontrolled infection~* Prior neuroaxis chemotherapy (lumbar puncture, reservoir, or systemic) allowed~* No other concurrent chemotherapy for other sites of disease~* No prior radiotherapy to areas of measurable meningeal disease unless there is clear radiographic progression in these areas~* No prior radiotherapy to greater than 30% of bone marrow~* Prior radiotherapy to the neuroaxis allowed~* No concurrent radiotherapy for other sites of disease or for progressive disease~* Recovered from any prior recent therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temozolomide (Type: EXPERIMENTAL): Oral temozolomide 75 mg/m2/day for 6 weeks, followed by 4 week break. Cycles will continue until:~* disease progression~* intolerable toxicity~* complete response - 2 full additional cycles~* if response is complete except for residual radiographic abnormalities that persist unchanged for 2 full cycles: continue for 4 cycles past best response.

Based on this trial design, predict the completion outcome and termination type (if applicable).